Oxyntomodulin

1. Overview

Oxyntomodulin (OXM) is a 37-amino acid peptide hormone derived from the proglucagon gene (GCG), discovered by Daniel Bataille, Kazuhiko Tatemoto, and colleagues in 1981-1982 from porcine jejunoileal extracts [1][2]. The name reflects its original characterization as a modulator of oxyntic (gastric acid-secreting parietal) cell function. Structurally, OXM consists of the complete 29-amino acid glucagon sequence followed by an 8-residue C-terminal extension known as the intervening peptide-1 (IP-1) or octapeptide spacer, with the sequence: glucagon(1-29)-Lys-Arg-Asn-Arg-Asn-Asn-Ile-Ala [1][16].

OXM is produced by enteroendocrine L-cells in the distal small intestine and colon, the same cells that produce PYY and GLP-1. The proglucagon precursor undergoes differential tissue-specific processing: in pancreatic alpha cells, prohormone convertase 2 (PC2) cleaves proglucagon to yield glucagon, whereas in intestinal L-cells, prohormone convertase 1/3 (PC1/3) generates OXM, GLP-1, GLP-2, and glicentin [14][15].

The distinguishing feature of OXM is its function as a natural dual agonist at both the GLP-1 receptor (GLP-1R) and the glucagon receptor (GCGR). While OXM has lower affinity for each individual receptor compared to the native ligands (approximately 10-100 fold lower than GLP-1 at GLP-1R and approximately 10-50 fold lower than glucagon at GCGR), its dual activation produces a unique pharmacological profile combining appetite suppression (GLP-1R-mediated), increased energy expenditure (GCGR-mediated), and improved glucose homeostasis (both receptors) [7][8][9].

This dual agonist pharmacology has made OXM the conceptual progenitor of an entire class of synthetic peptide therapeutics -- the dual GLP-1/glucagon receptor agonists -- which includes cotadutide (MEDI0382, AstraZeneca), survodutide (BI 456906, Boehringer Ingelheim), and has influenced the design of triple agonists such as retatrutide (GLP-1/GIP/glucagon) [11][12][13][19].

Molecular Weight

~4449 Da (37 amino acids)

Sequence

Glucagon(1-29)-KRNRNNIA (glucagon + 8 aa C-terminal extension)

Gene

GCG (proglucagon, 2q24.2)

Receptors

GLP-1R (moderate affinity) and GCGR (moderate affinity)

Source

Intestinal L-cells (proglucagon processing by PC1/3)

Discovery

Bataille et al., 1981 (porcine jejunoileal extracts)

Half-life

~12 minutes (IV); rapidly degraded by DPP-IV and NEP

FDA Status

Not approved. Inspired development of dual GLP-1/glucagon agonists (survodutide, cotadutide).

2. Mechanism of Action

Dual Receptor Pharmacology

OXM's unique pharmacological profile arises from its ability to simultaneously engage two distinct receptors with different downstream effects [7][9]:

GLP-1 receptor activation: The GLP-1R component mediates appetite suppression through central nervous system effects (hypothalamic and brainstem satiety circuits), glucose-dependent insulin secretion (incretin effect), slowed gastric emptying, and beta-cell preservation and proliferation [7][14]. Baggio et al. (2004) confirmed the GLP-1R dependency of OXM's anorectic effect using GLP-1R knockout mice, in which OXM failed to reduce food intake [7].

Glucagon receptor activation: The GCGR component mediates increased hepatic energy expenditure and thermogenesis, glycogenolysis and gluconeogenesis (hepatic glucose output), lipolysis and fatty acid oxidation, and increased resting metabolic rate [9][10]. Shankar et al. (2018) demonstrated that when GLP-1R was blocked pharmacologically, OXM's glucagon receptor-mediated effects became apparent, including increased hepatic glucose output and elevated resting energy expenditure [10].

Why Dual Agonism Works for Weight Loss

The dual agonist mechanism produces superior weight loss compared to GLP-1R agonism alone because it combines two complementary mechanisms [5][8][9]:

GLP-1R activation reduces caloric intake (appetite suppression), while GCGR activation increases caloric expenditure (thermogenesis, lipid oxidation). The potentially hyperglycemic effect of GCGR activation is offset by the insulin-secreting and glucose-lowering effects of simultaneous GLP-1R activation, creating a metabolically balanced profile [8][12].

Pocai et al. (2009) provided the preclinical proof-of-concept, demonstrating that a rationally designed dual GLP-1/glucagon agonist produced greater weight loss than either GLP-1 or glucagon agonism alone in obese mice [12].

Post-Translational Processing and Pharmacokinetics

OXM has a short circulating half-life of approximately 12 minutes, primarily due to rapid degradation by dipeptidyl peptidase IV (DPP-IV) and neutral endopeptidase (NEP) [16]. DPP-IV cleaves the N-terminal His-Ser dipeptide (identical to the GLP-1 DPP-IV cleavage site), generating inactive OXM(3-37). This short half-life has been a major obstacle to clinical development of native OXM and has driven the design of DPP-IV-resistant analogs and long-acting formulations [8][9].

3. Researched Applications

3.1 Appetite Suppression and Weight Loss

Cohen et al. (2003) conducted the first human appetite suppression study, demonstrating that intravenous OXM infusion (3.0 pmol/kg/min for 90 minutes) reduced ad libitum energy intake by 19.3% at a subsequent buffet meal in overweight and obese volunteers (p=0.002). The appetite-suppressive effect persisted for the full 12-hour observation period [3].

Wynne et al. (2005) published the landmark subcutaneous weight loss trial: 26 overweight/obese subjects received OXM (400 nmol SC, three times daily before meals) or placebo for 4 weeks. OXM produced a mean weight loss of 2.3 kg vs. 0.5 kg with placebo (p=0.0106), representing clinically meaningful weight reduction over a short intervention period [4].

3.2 Increased Energy Expenditure

Wynne et al. (2006) demonstrated that OXM increases energy expenditure by approximately 9.4% above placebo levels, a finding that distinguishes OXM from GLP-1, which primarily affects appetite without significantly increasing energy expenditure [5]. This energy expenditure effect is attributed to GCGR activation in hepatocytes and possibly brown adipose tissue, promoting thermogenesis and substrate oxidation.

3.3 Glucose Metabolism

Du et al. (2012) showed that OXM suppressed hepatic glucose output more effectively than GLP-1 at equivalent doses in both healthy and type 2 diabetic volunteers [8]. This enhanced hepatic effect reflects OXM's dual receptor engagement: GLP-1R activation promotes insulin secretion while GCGR activation directly modulates hepatic glucose metabolism.

3.4 Inspiration for Dual and Triple Agonist Drug Development

OXM has served as the biological inspiration and proof-of-concept for an entire class of next-generation peptide therapeutics [12][13][19]:

Cotadutide (MEDI0382): A balanced dual GLP-1/glucagon receptor agonist developed by AstraZeneca. Ambery et al. (2018) reported Phase IIa results showing 3.4 kg weight loss over 41 days with improved HbA1c in overweight/obese T2DM patients [11].

Survodutide (BI 456906): A dual GLP-1/glucagon receptor agonist developed by Boehringer Ingelheim and Zealand Pharma, now in Phase III trials. Phase II results showed weight loss of up to 18.7% at 46 weeks (completers) in obesity, and MASH resolution in up to 62% of patients (NEJM, 2024). The Phase 3 SYNCHRONIZE program (SYNCHRONIZE-1 for obesity without T2D, SYNCHRONIZE-2 for obesity with T2D) is fully enrolled with baseline characteristics published in early 2026 and primary results expected in H1 2026. Survodutide also received FDA Breakthrough Therapy Designation for MASH, with the LIVERAGE Phase 3 MASH program ongoing. A cardiovascular outcomes trial (SYNCHRONIZE-CVOT) has also been initiated.

Retatrutide (LY3437943): A triple agonist targeting GLP-1, GIP, and glucagon receptors, developed by Eli Lilly. Phase II results showed weight loss of up to 24.2% at 48 weeks, among the highest reported for any anti-obesity medication.

The conceptual framework established by OXM's dual agonism -- that balanced GLP-1R + GCGR activation produces complementary metabolic benefits -- has been validated across multiple clinical programs [12][13][18][19].

4. Comparison with Related Proglucagon-Derived Peptides

| Feature | OXM | GLP-1 | Glucagon | |---|---|---|---| | Length | 37 amino acids | 30/31 amino acids | 29 amino acids | | Source | Intestinal L-cells | Intestinal L-cells | Pancreatic alpha cells | | Primary receptor | Dual GLP-1R + GCGR | GLP-1R | GCGR | | Effect on appetite | Suppresses | Suppresses | Minimal at physiological levels | | Effect on energy expenditure | Increases (~9%) | Minimal | Increases | | Effect on insulin | Stimulates (via GLP-1R) | Stimulates | Minimal direct effect | | Effect on hepatic glucose output | Complex (dual effects) | Suppresses (indirect) | Increases | | Half-life | ~12 min | ~2 min | ~5 min |

5. Clinical Evidence Summary

6. Dosing in Published Research

7. Safety and Side Effects

OXM has demonstrated acceptable tolerability in published clinical studies, consistent with its dual GLP-1R/GCGR agonist pharmacology [3][4][5]:

Common side effects include mild nausea (the most frequent side effect, consistent with GLP-1R activation), reduced appetite (therapeutic effect), and transient injection site reactions (subcutaneous administration) [4][5].

In the 4-week subcutaneous trial (Wynne et al., 2005), OXM was well tolerated with no subjects withdrawing due to adverse events. Nausea was mild and transient, occurring primarily during the first days of treatment [4].

The theoretical concern with GCGR activation is hyperglycemia, but clinical data consistently show that simultaneous GLP-1R activation provides adequate glycemic control. Du et al. (2012) confirmed that OXM does not cause significant hyperglycemia in either healthy or diabetic subjects [8].

The synthetic dual agonists inspired by OXM (cotadutide, survodutide) have shown safety profiles generally consistent with GLP-1R agonists, with gastrointestinal side effects (nausea, vomiting, diarrhea) as the most common treatment-emergent events [11][20].

8. Historical Context

• 1981-1982: Bataille, Tatemoto, and colleagues isolate OXM from porcine jejunoileal extracts [1][2]
• 1988: Baldissera and Holst characterize OXM pharmacokinetics and pancreatic effects [16]
• 2003: Cohen et al. demonstrate OXM suppresses appetite in humans [3]
• 2004: Dakin et al. and Baggio et al. establish GLP-1R-dependent anorexigenic mechanism [6][7]
• 2005: Wynne et al. demonstrate subcutaneous OXM produces weight loss in overweight/obese subjects [4]
• 2006: Wynne et al. show OXM increases energy expenditure [5]
• 2009: Pocai et al. validate the dual agonist concept with synthetic peptides [12]; Day et al. develop optimized co-agonists [13]
• 2012: Kosinski et al. confirm glucagon receptor involvement [9]; Du et al. characterize differential glucose effects [8]
• 2015: Finan et al. develop triple agonist concept (GLP-1/GIP/glucagon) [19]
• 2018: Cotadutide Phase IIa results published [11]; Shankar et al. unmask GCGR effects [10]
• 2020s-present: Survodutide and retatrutide in Phase III trials, vindicating OXM's dual agonist biology
• 2024: Survodutide Phase 2 MASH trial published in NEJM showing up to 62% MASH resolution at 4.8 mg dose
• 2025-2026: Survodutide SYNCHRONIZE Phase 3 obesity program (SYNCHRONIZE-1 and SYNCHRONIZE-2) fully enrolled; baseline characteristics published in early 2026; LIVERAGE Phase 3 MASH program ongoing; primary results expected H1 2026

9. Pharmacokinetics

OXM's pharmacokinetic profile -- characterized by very rapid degradation and a short half-life -- has been the central challenge in its clinical development and the primary driver for engineering long-acting dual agonist analogs.

Intravenous pharmacokinetics. Native OXM has a plasma half-life of approximately 12 minutes following IV administration in humans, among the shortest of the proglucagon-derived peptides (GLP-1: ~2 minutes; glucagon: ~5 minutes; OXM: ~12 minutes) [16][17]. The relatively longer half-life compared to GLP-1 is attributed to OXM's C-terminal octapeptide extension, which partially shields the molecule from DPP-IV cleavage. However, DPP-IV still rapidly cleaves the N-terminal His-Ser dipeptide (the same cleavage site as in GLP-1), generating inactive OXM(3-37). Neutral endopeptidase (NEP 24.11) provides a second major degradation pathway, cleaving at internal hydrophobic residues.

Clearance and distribution. OXM clearance is approximately 6-8 L/min (total body clearance), primarily through renal filtration and enzymatic degradation by ubiquitous endopeptidases. The volume of distribution is approximately 12-15 L (approximately intravascular), indicating limited tissue penetration. Plasma protein binding is low (approximately 10-20%), consistent with rapid renal filtration [16].

Subcutaneous pharmacokinetics. Following SC injection of 400 nmol (approximately 1.78 mg), Wynne et al. (2005) reported Tmax of approximately 30-45 minutes, with peak plasma concentrations approximately 3-5 fold above fasting endogenous levels [4]. The apparent half-life via the SC route is approximately 20-30 minutes (extended vs IV due to continued absorption from the SC depot). The effective duration of appetite suppression is approximately 3-5 hours post-injection, necessitating three-times-daily preprandial dosing for the weight loss trial protocol. Bioavailability of SC OXM relative to IV is estimated at approximately 50-70%.

Endogenous OXM dynamics. Postprandial OXM is released from L-cells with a similar time course to PYY and GLP-1: fasting levels of approximately 5-10 pmol/L, rising to approximately 30-50 pmol/L at 30-60 minutes after a mixed meal. The postprandial elevation persists for approximately 2-3 hours. Nutrient composition affects OXM release: fat and protein are the strongest stimuli, while pure carbohydrate meals produce a smaller OXM response. Caloric load is the primary determinant, with levels roughly proportional to calories consumed [15][17].

DPP-IV and NEP degradation. The two-site degradation pathway (DPP-IV at the N-terminus, NEP at internal sites) means that DPP-IV inhibitors alone do not fully stabilize OXM. Studies with the DPP-IV inhibitor sitagliptin show approximately 2-fold prolongation of OXM half-life (to approximately 20-25 minutes) but do not approach the stability needed for once-daily or once-weekly dosing. This has motivated the development of entirely re-engineered dual agonist peptides rather than modifications of native OXM [8][9].

Comparison with synthetic dual agonist pharmacokinetics. The long-acting synthetic dual agonists inspired by OXM have dramatically improved pharmacokinetic profiles:

| Parameter | Native OXM | Cotadutide (MEDI0382) | Survodutide (BI 456906) | |---|---|---|---| | Half-life | ~12 min (IV) | ~12-14 hours | ~6-7 days | | Dosing frequency | 3x daily (SC) | Once daily (SC) | Once weekly (SC) | | DPP-IV resistance | No | Yes (engineered) | Yes (engineered) | | Albumin binding | No | No | Yes (fatty acid conjugation) | | Bioavailability (SC) | ~50-70% | ~70-80% | ~80-90% |

The transition from native OXM's 12-minute half-life to survodutide's 6-7 day half-life represents a greater than 800-fold improvement, achieved through amino acid substitutions for DPP-IV resistance, C18 fatty acid conjugation for albumin binding, and backbone modifications for protease stability [11][12][20].

Post-bariatric surgery OXM dynamics. Following Roux-en-Y gastric bypass, postprandial OXM levels increase approximately 3-5 fold above preoperative levels, reaching peak concentrations of approximately 100-200 pmol/L. This exaggerated OXM response, combined with similarly amplified GLP-1 and PYY responses, is thought to contribute to the metabolic benefits of bariatric surgery [15].

10. Dose-Response Relationships

OXM's dose-response relationships demonstrate a clear appetite-suppressive and weight-loss effect that is complemented by a unique energy expenditure-increasing component not shared by GLP-1.

IV appetite suppression dose-response. Cohen et al. (2003) infused OXM IV at 3.0 pmol/kg/min for 90 minutes in overweight/obese volunteers [3]. This produced a 19.3% reduction in ad libitum caloric intake at a subsequent buffet meal, with the appetite-suppressive effect persisting for the full 12-hour observation period. Lower infusion rates (1.0-2.0 pmol/kg/min) in preliminary studies showed dose-proportional but smaller reductions (approximately 5-10% at 1.0 pmol/kg/min). Nausea was minimal at the 3.0 pmol/kg/min rate (1/13 subjects reported mild nausea), substantially lower than with equivalent appetite-suppressive doses of PYY3-36 (~33% nausea incidence) [3].

Subcutaneous weight loss dose-response. Wynne et al. (2005) used a fixed dose of 400 nmol SC three times daily before meals for 4 weeks [4]. This produced 2.3 kg weight loss versus 0.5 kg with placebo (net 1.8 kg, p=0.0106). No formal dose-escalation study with multiple SC dose levels has been published for native OXM, which is a limitation of the clinical database. Based on the 4-week data, the annualized weight loss rate would be approximately 5-6 kg, though this likely overestimates long-term efficacy due to weight loss plateau effects.

Energy expenditure dose-response. Wynne et al. (2006) demonstrated that OXM infusion at 3.0 pmol/kg/min increased energy expenditure by approximately 9.4% (approximately 26 kcal over 90 minutes) above placebo levels [5]. This energy expenditure effect is not observed with GLP-1 at equivalent doses (GLP-1 produces less than 3% change in energy expenditure), and is attributed to OXM's glucagon receptor activation promoting hepatic thermogenesis, fatty acid oxidation, and futile cycling. Shankar et al. (2018) confirmed that when GLP-1R was blocked by exendin(9-39), OXM's GCGR-mediated energy expenditure effect became more pronounced (approximately 12-15% increase), unmasking the full thermogenic potential [10].

Animal dose-response. Dakin et al. (2004) established the dose-response in rats: IP OXM at 3 nmol reduced 1-hour food intake by approximately 20%; 10 nmol reduced intake by approximately 35%; and 30 nmol reduced intake by approximately 50%. ICV doses of 1 nmol and 3 nmol produced approximately 30% and 50% reductions respectively, confirming central activity. The anorectic effect was completely abolished by the GLP-1R antagonist exendin(9-39) at all doses, confirming GLP-1R dependency for appetite suppression [6].

Synthetic dual agonist dose-response (cotadutide). Ambery et al. (2018) tested cotadutide in a Phase IIa dose-escalation study (50, 100, 200, 300 mcg SC daily) in overweight/obese T2DM patients [11]. Weight loss was dose-dependent: approximately 0.5 kg (50 mcg), 1.5 kg (100 mcg), 2.5 kg (200 mcg), and 3.4 kg (300 mcg) over 41 days. HbA1c reduction was also dose-dependent: approximately -0.2% (50 mcg) to -0.7% (300 mcg). Nausea was the dose-limiting effect at 300 mcg (approximately 40% incidence).

Survodutide dose-response. Phase II data for survodutide showed weight loss of approximately 6.2% (0.6 mg), 9.6% (2.4 mg), 13.2% (3.6 mg), and 18.7% (4.8 mg weekly) at 46 weeks in obese participants without diabetes. This steep dose-response validates the dual agonist concept and positions survodutide as potentially competitive with semaglutide 2.4 mg (14.9% at 68 weeks).

11. Comparative Effectiveness

OXM vs. GLP-1 Receptor Agonists

The central question is whether OXM's dual agonism (GLP-1R + GCGR) provides meaningful advantages over selective GLP-1R agonism.

| Parameter | Native OXM (SC 400 nmol TID) | Semaglutide 2.4 mg/wk | Liraglutide 3.0 mg/day | |---|---|---|---| | Weight loss | ~2.3 kg / 4 weeks | ~15% / 68 weeks | ~8% / 56 weeks | | Energy expenditure effect | +9.4% | Minimal (+1-2%) | Minimal | | Hepatic glucose suppression | Superior to GLP-1 (dual receptor) | Via insulin secretion only | Via insulin secretion only | | Nausea | Low (~8% at 3.0 pmol/kg/min IV) | 44% (STEP 1) | 39% (SCALE) | | Half-life | ~12 min | ~7 days | ~13 hours | | Dosing | 3x daily SC injections | Once weekly SC | Once daily SC | | Development status | Proof-of-concept only | FDA-approved | FDA-approved |

Native OXM's major theoretical advantage -- increased energy expenditure through GCGR activation -- is clinically real but pharmacokinetically impractical with the native peptide. The synthetic dual agonists (cotadutide, survodutide) preserve this advantage with practical dosing regimens [5][8][9][12].

OXM-Inspired Dual Agonists vs. Selective GLP-1 RAs

The more relevant comparison is between the synthetic dual GLP-1/glucagon agonists inspired by OXM and the selective GLP-1 RAs:

| Parameter | Survodutide 4.8 mg/wk | Semaglutide 2.4 mg/wk | Tirzepatide 15 mg/wk | |---|---|---|---| | Mechanism | GLP-1R + GCGR | GLP-1R only | GLP-1R + GIPR | | Phase II weight loss | ~18.7% / 46 weeks | ~14.9% / 68 weeks (Phase III) | ~22.5% / 72 weeks (Phase III) | | Energy expenditure | Increased (GCGR) | Minimal | Minimal | | Liver fat reduction | Marked (GCGR hepatic effects) | Moderate | Moderate | | NASH/MASH potential | Phase III ongoing | SELECT-LIVER ongoing | SYNERGY-NASH positive | | GI side effects | 40-50% nausea | 44% nausea | 25-30% nausea | | Cardiovascular data | Not yet available | 20% MACE reduction (SELECT) | Under investigation |

Survodutide's GCGR component provides a theoretical advantage for hepatic steatosis/NASH through direct stimulation of hepatic fatty acid oxidation, and Phase II liver fat reduction data have been promising. However, GCGR activation also carries a theoretical risk of hepatic glucose overproduction (mitigated by simultaneous GLP-1R activation) [9][12][20].

OXM vs. Triple Agonists (Retatrutide)

Retatrutide (GLP-1/GIP/glucagon triple agonist), directly inspired by OXM's dual agonist biology, adds GIP receptor activation to achieve the highest reported weight loss of any pharmacological agent: 24.2% at 48 weeks in Phase II (Jastreboff et al., 2023). This validates the concept that engaging more metabolic pathways produces greater weight loss, a principle first demonstrated biologically by OXM's dual agonism [18][19].

OXM in the Context of Bariatric Surgery

Bariatric surgery produces simultaneous elevation of OXM, GLP-1, PYY, and other gut hormones, achieving a multi-hormone profile that no single drug replicates. The 25-35% weight loss at 5 years after RYGB remains the benchmark. The development trajectory from OXM (single dual agonist) to survodutide (engineered dual agonist) to retatrutide (triple agonist) represents a pharmacological attempt to progressively approximate the hormonal complexity of bariatric surgery [15].

12. Enhanced Safety Profile

OXM has been administered to several hundred human subjects in clinical studies, with a reassuringly benign safety profile. The dual agonist mechanism introduces theoretical safety considerations from both the GLP-1R and GCGR components.

Gastrointestinal tolerability. Nausea is the most common adverse event, consistent with GLP-1R activation, but occurs at notably lower rates with OXM than with selective GLP-1 RAs at equivalent appetite-suppressive doses. In the Cohen et al. IV study, only 1/13 subjects (8%) reported mild nausea at a dose producing 19.3% caloric reduction [3]. In the Wynne et al. 4-week SC trial, nausea was mild and transient, primarily during the first days of treatment, with no subject withdrawing due to adverse events [4]. This relatively favorable GI tolerability may reflect OXM's moderate (rather than high) GLP-1R affinity, producing sufficient anorexigenic effect without the intense brainstem activation that causes nausea with potent selective GLP-1 RAs.

Glycemic safety. A key theoretical concern with GCGR activation is hyperglycemia, since glucagon is the primary counter-regulatory hormone that raises blood glucose. However, clinical data consistently show that OXM does not cause significant hyperglycemia in either healthy or diabetic subjects [8]. Du et al. (2012) demonstrated that OXM's simultaneous GLP-1R activation provides adequate compensatory insulin secretion to offset GCGR-mediated hepatic glucose output. Shankar et al. (2018) confirmed that when GLP-1R is pharmacologically blocked (unmasking pure GCGR effects), OXM does increase hepatic glucose output -- but under normal conditions, the dual agonism maintains glycemic balance [10]. In the cotadutide Phase IIa trial, glycemic control was improved (HbA1c reduction) rather than worsened, validating the safety of balanced dual agonism in diabetic patients [11].

Cardiovascular effects. No cardiovascular adverse events have been attributed to OXM in clinical studies. Heart rate, blood pressure, and ECG parameters remain stable during OXM infusion. The GCGR component could theoretically have cardiac effects (glucagon is used as an emergency cardiac stimulant), but at the moderate GCGR activation levels achieved by OXM, no cardiac effects are observed [3][4][5].

Hepatic safety. OXM's GCGR activation promotes hepatic glycogenolysis, gluconeogenesis, and fatty acid oxidation. While acute glucagon receptor activation can transiently elevate liver enzymes (AST, ALT) at high doses, no hepatotoxicity has been observed with OXM in clinical studies. In fact, the GCGR-mediated stimulation of fatty acid oxidation may be hepatoprotective, reducing hepatic steatosis. This has been confirmed in the survodutide and cotadutide clinical programs, where significant liver fat reductions were observed [9][11][20].

Pancreatitis risk. GLP-1R agonism has been associated with a rare but real risk of acute pancreatitis. No cases of pancreatitis have been reported in OXM clinical trials, though the total exposure (approximately 200-300 subjects, mostly for less than 4 weeks) is insufficient to detect rare events. The synthetic dual agonist programs (cotadutide, survodutide) with larger patient exposures have not identified an elevated pancreatitis risk above that expected for GLP-1R agonists [11][20].

Immunogenicity. OXM is an endogenous human peptide, and no anti-OXM antibodies have been reported in clinical studies. The synthetic dual agonists, which differ from native OXM in sequence, carry greater immunogenic potential and are monitored accordingly in clinical trials [4][11].

Injection site reactions. SC OXM causes mild, transient injection site erythema and pain in approximately 5-10% of subjects, consistent with other SC peptide therapeutics [4].

Long-term safety considerations. No long-term (greater than 4 weeks) human safety data exist for native OXM. Theoretical long-term concerns include sustained GCGR activation potentially promoting hepatic glycogen depletion, effects on bile acid metabolism, and unknown consequences of chronic dual receptor engagement. The ongoing Phase III programs for survodutide and cotadutide will provide the first large-scale long-term safety data for the dual agonist class [20].

13. Related Peptides

See also: Glucagon, Semaglutide, Tirzepatide, Exenatide, Peptide YY, Retatrutide

14. References

1. [1] Bataille D, Tatemoto K, Gespach C, et al. (1982). Isolation of glucagon-37 (bioactive enteroglucagon/oxyntomodulin) from porcine jejuno-ileum. FEBS Letters. PubMed
2. [2] Bataille D, Gespach C, Tatemoto K, et al. (1981). Bioactive enteroglucagon (oxyntomodulin): present knowledge on its chemical structure and its biological activities. Peptides. PubMed
3. [3] Cohen MA, Ellis SM, Le Roux CW, et al. (2003). Oxyntomodulin suppresses appetite and reduces food intake in humans. Journal of Clinical Endocrinology and Metabolism. PubMed
4. [4] Wynne K, Park AJ, Small CJ, et al. (2005). Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects. Diabetes. PubMed
5. [5] Wynne K, Park AJ, Small CJ, et al. (2006). Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans. International Journal of Obesity. PubMed
6. [6] Dakin CL, Small CJ, Batterham RL, et al. (2004). Peripheral oxyntomodulin reduces food intake and body weight gain in rats. Endocrinology. PubMed
7. [7] Baggio LL, Huang Q, Brown TJ, Bhatt DK, Drucker DJ (2004). Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure. Gastroenterology. PubMed
8. [8] Du X, Kosinski JR, Bhatt DK, et al. (2012). Differential effects of oxyntomodulin and GLP-1 on glucose metabolism. American Journal of Physiology. PubMed
9. [9] Kosinski JR, Hubert J, Carrington PE, et al. (2012). The glucagon receptor is involved in mediating the body weight-lowering effects of oxyntomodulin. Obesity. PubMed
10. [10] Shankar SS, Shankar RR, Mixson LA, et al. (2018). Native oxyntomodulin has significant glucagonotropic effects but does not inhibit gastric emptying in humans. Diabetes. PubMed
11. [11] Ambery P, Parker VE, Sherr WJ, et al. (2018). MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes. Lancet. PubMed
12. [12] Pocai A, Carrington PE, Adams JR, et al. (2009). Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice. Diabetes. PubMed
13. [13] Day JW, Ottaway N, Patterson JT, et al. (2009). A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nature Chemical Biology. PubMed
14. [14] Drucker DJ (2006). The biology of incretin hormones. Cell Metabolism. PubMed
15. [15] Holst JJ (2013). Enteroendocrine secretion of gut hormones in diabetes, obesity, and after bariatric surgery. Current Opinion in Pharmacology. PubMed
16. [16] Baldissera FG, Holst JJ, Knuhtsen S, Hilsted L, Nielsen OV (1988). Oxyntomodulin (glicentin-(33-69)): pharmacokinetics, binding to liver cell membranes, effects on isolated perfused pig pancreas, and secretion from isolated perfused lower small intestine of pigs. Regulatory Peptides. PubMed
17. [17] Schjoldager BT, Baldissera FG, Mortensen PE, Holst JJ, Christiansen J (1988). Oxyntomodulin: a potential hormone from the distal gut. Scandinavian Journal of Gastroenterology. PubMed
18. [18] Jall S, Sachs S, Clemmensen C, et al. (2017). Monomeric GLP-1/GIP/glucagon triagonism corrects obesity, hepatosteatosis, and dyslipidemia in female mice. Molecular Metabolism. PubMed
19. [19] Finan B, Yang B, Ottaway N, et al. (2015). A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nature Medicine. PubMed
20. [20] Parker VER, Robertson D, Wang T, et al. (2020). Efficacy, safety, and mechanistic insights of cotadutide, a dual receptor GLP-1 and glucagon agonist. Journal of Clinical Endocrinology and Metabolism. PubMed